Close menu




October 9th, 2025 | 07:40 CEST

AI paves the way to the next blockbuster: The current situation at Novo Nordisk, NetraMark Holdings and Evotec

  • AI
  • Biotechnology
  • Biotech
Photo credits: pixabay.com

The pharmaceutical industry is at a historic turning point. Artificial intelligence is breaking through the lengthy and costly development cycles that have characterized the sector for decades. This technological quantum leap is revolutionizing drug discovery and promises to transform healthcare from the ground up. The first companies to master this AI revolution will be the biggest winners in a billion-dollar market. We therefore take a look at three companies that are already using AI today: the Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings for clinical studies, and the German research service provider Evotec, and analyze their current situation.

time to read: 4 minutes | Author: Armin Schulz
ISIN: NOVO NORDISK A/S | DK0062498333 , NETRAMARK HOLDINGS INC | CA64119M1059 , EVOTEC SE INH O.N. | DE0005664809

Table of contents:


    Novo Nordisk – From market darling to hidden gem?

    Novo Nordisk is a heavyweight in the pharmaceutical sector specializing in diabetes and obesity medications. Its best-known product, the weight loss drug Wegovy, has catapulted the Company into the absolute top tier in recent years. Together with its US competitor Eli Lilly, it dominates the market for modern metabolic therapies. The barriers to entry in this field are enormous, characterized by long development times, high regulatory hurdles, and billions in investments in production and distribution. This dominant position caused the Company's valuation to skyrocket, driven by almost unbridled growth expectations.

    But the exaggerated expectations collided with reality. The Company was forced to revise its growth forecasts downwards several times. The reasons for this were production bottlenecks that could not meet the strong demand for Wegovy, as well as intensifying competitive pressure. Added to this were regulatory uncertainties, price pressure, and the high costs of urgently needed expansion of production capacity. In this tense situation, management changes and restructuring measures also led to uncertainty.

    Even if the exorbitant growth rates of the early days can no longer be achieved, the global market for obesity therapies will continue to grow in the coming years. Novo Nordisk has the potential to benefit from this trend thanks to its deep integration in production and distribution and a robust pipeline. Particularly promising is the development of an oral version of Wegovy, which could significantly expand the pool of potential patients. For investors who are prepared to sit out the current turbulence, the Company could prove to be an interesting entry point into a structurally growing business segment. The share price is currently trading at EUR 50.52.

    NetraMark Holdings – When AI makes clinical trials smarter

    Clinical trials are the backbone of the pharmaceutical industry, yet their high risk of failure costs billions. This is precisely where NetraMark steps in with an innovative approach. Instead of relying on historical data like many of its competitors, the Company applies its AI platform, NetraAI, directly to data from ongoing or completed studies. A specialized algorithm identifies hidden patterns and divides patients into explainable subgroups. This helps to understand the effectiveness of therapies more precisely and to better predict side effects. For the pharmaceutical industry, this represents an opportunity to design studies in a more targeted manner and reduce costly failures.

    Growth is driven by strategic alliances. A global partnership with the contract research organization Worldwide Clinical Trials paves the way to numerous customers in the pharmaceutical industry. Collaboration with Pentara aims to use AI to monitor data integrity in study centers. In addition, partnerships with Asklepion Pharmaceuticals in pediatrics and a leading US research center for aggressive glioblastoma provide concrete use cases. These projects demonstrate the broad applicability of the technology across different therapeutic areas and study phases.

    The combination of technological strength and a growing partner network optimally positions NetraMark in a growing billion-dollar market. The pharmaceutical industry has an enormous need to make its studies more efficient and meaningful, a demand that AI is increasingly able to address. NetraMark's stated goal is to use its AI to address this very issue and fundamentally improve the development process for new drugs. The partnerships already established with well-known players are a strong indication that the industry has recognized the solution. Analysts at Zacks Small-Cap Research see a price target of CAD 2.25. The stock is currently trading at CAD 1.37.

    Evotec – Where does the drug developer really stand?

    The latest figures from Hamburg-based life sciences company Evotec paint a picture of contrasts. In the first half of the year, the Company suffered a decline in revenue of around 5% to EUR 371 million. This weakness was driven by its core business of drug discovery (D&PD), where revenues slumped by 11%. However, there is a clear ray of hope. The Just – Evotec Biologics (JEB) division grew strongly by 16%. This contrasting development underscores the strategic change that has been initiated. Evotec is deliberately transforming itself from a capital-intensive service provider to a scalable technology provider that relies on proprietary platforms.

    This realignment is being driven by groundbreaking partnerships. The collaboration with Bristol Myers Squibb in the areas of neurodegeneration and targeted protein degradation not only generates significant milestone payments but also anchors Evotec deeply in innovative fields of research. At the same time, the alliance with Sandoz is being realigned. The planned sale of the biologics production site in Toulouse is intended to free up capital and further advance the asset-light model. The focus is thus shifting definitively from in-house production to licensing the promising perfusion-based manufacturing technology.

    For investors, the situation represents a trade-off between short-term weakness and long-term potential. While performance is dampened by the downturn in the D&PD business, strict cost discipline limited the EBITDA loss to EUR 1.9 million. Despite these operational challenges, analysts see significant upside potential, supported by the more profitable JEB division and the expected market recovery in the active ingredient market. Investors confident in the Company's technology transformation and platform strength may view the current consolidation as a buying opportunity. In August and September, two of the Company's executive bodies purchased shares totaling around EUR 370,000 at approximately EUR 5.92. The share is currently trading at EUR 6.83.


    The AI-driven race for the next blockbuster drugs is in full swing, but the paths taken by the companies could not be more different. Following its growth dip, Novo Nordisk must now deliver and overcome production bottlenecks in order to realize its enormous sales potential. NetraMark Holdings scores as an AI specialist with clever solutions to make clinical trials more efficient and meaningful. Meanwhile, Evotec is in the midst of a painful but necessary strategic shift from service provider to scalable technology provider. Those who master AI today will write billion-dollar success stories tomorrow.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Carsten Mainitz on November 19th, 2026 | 05:20 CET

    Uranium and Reactor Technology: Standard Uranium, Cameco and SGL Carbon – Who Benefits Most from the Nuclear Comeback?

    • Uranium
    • Nuclear power
    • Nuclear energy
    • Reactors
    • Reactor technology
    • AI
    • Supply chains

    Nuclear power needs fresh supplies! Longer operating lifetimes, new reactors and power-hungry data centres are strengthening demand and fuelling optimism for the industry. Geopolitical tensions are pushing operators to secure supplies, while additional supply requires substantial capital and time. For investors, this opens up opportunities along the entire nuclear value chain. Standard Uranium starts at the very beginning, exploring for new deposits in Canada's Athabasca region. Cameco already generates revenue from uranium and fuel services and is also involved in reactor technology through Westinghouse. SGL Carbon, in turn, supplies speciality graphite for X-energy's reactors and recently secured another order worth around USD 90 million. Which company will take off now?

    Read

    Commented by Jens Castner on November 18th, 2026 | 05:40 CET

    Treasures from the depths, a slump in the stock market: Lynas, Almonty and Cameco tempt with low share prices

    • Critical raw materials
    • Rare earths
    • Tungsten
    • Uranium
    • Almonty Industries
    • Cameco
    • AI
    • Lynas Rare Earths

    Without rare earths, no electric motors; without tungsten, no defence industry; without uranium, no nuclear power. The West needs these raw materials more urgently than ever and depends on a handful of suppliers that mine in politically stable countries. Yet shares in Lynas Rare Earths, Almonty Industries and Cameco are falling as if there were no shortage – down by one-third to two-thirds from their highs for the year. We have taken a close look at the three producers following their latest quarterly results. One of the shares has reached bargain levels.

    Read